Literature DB >> 21461679

Prognosis of intractable epilepsy: is long-term seizure freedom possible with medical management?

Heidi Munger Clary1, Hyunmi Choi.   

Abstract

Until recently, very little data existed on long-term seizure prognosis of patients with intractable epilepsy. We review recent work that assessed seizure remission in patients with intractable epilepsy during medical management. Recent prevalence cohort studies among adults with longstanding intractable epilepsy have demonstrated notable proportions of patients attaining at least 1-year seizure freedom, ranging from more than 10% to nearly 30% of patients, when followed for mean duration of 18 months to 6 years. Additionally, a recent prospective cohort study of pediatric-onset intractable epilepsy (followed prospectively for seizure outcome from onset of intractability) revealed minimum 1-year seizure remission among more than half of study patients. Despite the notable rates of remission seen among patients with intractable epilepsy, many individuals experienced subsequent seizure relapse. These findings highlight the continued importance of surgical therapy for those who are good candidates and the need for further development of effective therapeutic interventions.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21461679     DOI: 10.1007/s11910-011-0199-6

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


  27 in total

Review 1.  Comparison of the efficacy and tolerability of new antiepileptic drugs: what can we learn from long-term studies?

Authors:  G Zaccara; A Messori; M Cincotta; G Burchini
Journal:  Acta Neurol Scand       Date:  2006-09       Impact factor: 3.209

2.  A follow-up study of intractable seizures in childhood.

Authors:  P R Huttenlocher; R J Hapke
Journal:  Ann Neurol       Date:  1990-11       Impact factor: 10.422

3.  Results of treatment changes in patients with apparently drug-resistant chronic epilepsy.

Authors:  Anna L Luciano; Simon D Shorvon
Journal:  Ann Neurol       Date:  2007-10       Impact factor: 10.422

4.  Pharmacoresistant epilepsy: if at first you don't succeed...

Authors:  Tina Shih; Daniel Lowenstein
Journal:  Ann Neurol       Date:  2007-10       Impact factor: 10.422

5.  How long does it take for epilepsy to become intractable? A prospective investigation.

Authors:  Anne T Berg; Barbara G Vickrey; Francine M Testa; Susan R Levy; Shlomo Shinnar; Frances DiMario; Susan Smith
Journal:  Ann Neurol       Date:  2006-07       Impact factor: 10.422

6.  Predicting long-term seizure outcome after resective epilepsy surgery: the multicenter study.

Authors:  S S Spencer; A T Berg; B G Vickrey; M R Sperling; C W Bazil; S Shinnar; J T Langfitt; T S Walczak; S V Pacia
Journal:  Neurology       Date:  2005-09-27       Impact factor: 9.910

7.  New-onset temporal lobe epilepsy in children: lesion on MRI predicts poor seizure outcome.

Authors:  C G Spooner; S F Berkovic; L A Mitchell; J A Wrennall; A S Harvey
Journal:  Neurology       Date:  2006-11-02       Impact factor: 9.910

8.  Quantifying the response to antiepileptic drugs: effect of past treatment history.

Authors:  Yitzhak Schiller; Yussef Najjar
Journal:  Neurology       Date:  2008-01-01       Impact factor: 9.910

9.  Long-term outcome of nonsurgical candidates with medically refractory localization-related epilepsy.

Authors:  Linda M Selwa; Shelley L Schmidt; Beth A Malow; Ahmad Beydoun
Journal:  Epilepsia       Date:  2003-12       Impact factor: 5.864

10.  EEG and other early predictors of epilepsy remission: a community study.

Authors:  S Q Shafer; W A Hauser; J F Annegers; D W Klass
Journal:  Epilepsia       Date:  1988 Sep-Oct       Impact factor: 5.864

View more
  1 in total

1.  Longitudinal course of epilepsy in Rett syndrome and related disorders.

Authors:  Daniel C Tarquinio; Wei Hou; Anne Berg; Walter E Kaufmann; Jane B Lane; Steven A Skinner; Kathleen J Motil; Jeffrey L Neul; Alan K Percy; Daniel G Glaze
Journal:  Brain       Date:  2016-12-21       Impact factor: 13.501

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.